A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. [electronic resource]
Producer: 20120227Description: 326-33 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Clinical Trials, Phase II as Topic -- statistics & numerical data
- Combined Modality Therapy
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Fatigue -- chemically induced
- Female
- Hematologic Diseases -- chemically induced
- Hematopoietic Stem Cell Transplantation
- Humans
- Kaplan-Meier Estimate
- Lenalidomide
- Male
- Middle Aged
- Multicenter Studies as Topic -- statistics & numerical data
- Multiple Myeloma -- drug therapy
- Peripheral Nervous System Diseases -- chemically induced
- Pyrazines -- administration & dosage
- Retrospective Studies
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.